<DOC>
	<DOCNO>NCT01674322</DOCNO>
	<brief_summary>The purpose study investigate absorption , metabolic pathway excretion ibrutinib healthy male adult participant administration single oral dose 50 mg 140 mg ( 5 mg/mL solution ) unlabeled ibrutinib admixed 14C ibrutinib .</brief_summary>
	<brief_title>A Study Determine Absorption , Metabolism , Routes Excretion ( 14C ) Radiolabeled Ibrutinib Healthy Male Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , single-dose study healthy male participant . Six men enrol allow minimum 4 participant complete study . All participant receive single oral solution dose 50 140 mg ibrutinib contain 1480 kBq ( 40 µCi ) 14C label ibrutinib , constitute total radiation burden approximately 0.916 mSv ( ICRP risk category IIa ) . The duration study approximately 73 day include screening period 28 day , treatment period 15 day , follow-up period 30 day . Safety include adverse event , laboratory safety , 12 lead electrocardiogram , physical examination , vital sign .</detailed_description>
	<criteria>Participant must sign informed consent document indicate understand purpose procedure require study , include DNA analysis , willing participate study Must agree use adequate contraception method deem appropriate investigator ( eg , vasectomy , doublebarrier , partner use effective contraception ) study 3 month receive study drug Must agree donate sperm study 3 month receive study drug Blood pressure ( participant supine 5 minute ) 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic Nonsmoker ( smoke 6 month prior screen ) History current clinically significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease Clinically significant abnormal value hematology , coagulation platelet function , clinical chemistry urinalysis screening deem appropriate investigator Clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram ( ECG ) screening deem appropriate investigator History clinically significant allergy , especially know hypersensitivity intolerance βlactam antibiotic sulfonamide Known allergy heparin history heparin induce thrombocytopenia</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>B-cell malignancy</keyword>
	<keyword>CYP3A4</keyword>
</DOC>